Elicio Therapeutics, Inc. 8-K

What Happened
Elicio Therapeutics, Inc. (ELTX) announced its financial results for the year ended December 31, 2025 and provided corporate updates in an 8-K filed March 12, 2026. The company furnished the full text of the press release reporting those results as Exhibit 99.1 to the filing. The 8-K states that the information (including Exhibit 99.1) is furnished and not “filed” for purposes of Section 18 of the Securities Exchange Act.

Key Details

• Announcement date: March 12, 2026.
• Reporting period: year ended December 31, 2025.
• Press release is furnished as Exhibit 99.1 to the Form 8-K.
• Filing signed by Robert Connelly, President and Chief Executive Officer.
• Filing includes the standard disclosure that the furnished material is not subject to Section 18 liabilities and is not incorporated by reference unless expressly stated.

Why It Matters
This 8-K signals that Elicio has released its full-year results and corporate updates; investors should review the Exhibit 99.1 press release for details on earnings, revenue, cash position, guidance or other material metrics. Because the release is furnished (not “filed”), the company limits certain legal liabilities under Section 18—however, the content still provides the company’s official summary of its 2025 performance and management commentary.